The [choroid plexus](/entities/choroid-plexus), a highly vascularized structure residing within the brain ventricles, serves as the primary site of [cerebrospinal fluid](/entities/csf) (CSF) production and represents a critical interface between the systemic circulation and the central nervous system. In [Alzheimer's disease](/diseases/alzheimers-disease) (AD), the choroid plexus undergoes significant structural and functional changes that contribute to disease pathogenesis through multiple mechanisms including impaired CSF production, defective waste clearance, [blood-CSF barrier](/entities/blood-csf-barrier) breakdown, and altered signaling between the brain and peripheral systems.
The choroid plexus consists of epithelial cells that form the blood-CSF barrier, actively secreting CSF while regulating the passage of molecules between blood and brain. This structure also serves as a gateway for immune cell trafficking and produces numerous growth factors and signaling molecules essential for brain homeostasis. Understanding choroid plexus dysfunction in AD provides insights into disease mechanisms and potential therapeutic targets.
The [choroid plexus](/entities/choroid-plexus), a highly vascularized structure residing within the brain ventricles, serves as the primary site of [cerebrospinal fluid](/entities/csf) (CSF) production and represents a critical interface between the systemic circulation and the central nervous system. In [Alzheimer's disease](/diseases/alzheimers-disease) (AD), the choroid plexus undergoes significant structural and functional changes that contribute to disease pathogenesis through multiple mechanisms including impaired CSF production, defective waste clearance, [blood-CSF barrier](/entities/blood-csf-barrier) breakdown, and altered signaling between the brain and peripheral systems.
The choroid plexus consists of epithelial cells that form the blood-CSF barrier, actively secreting CSF while regulating the passage of molecules between blood and brain. This structure also serves as a gateway for immune cell trafficking and produces numerous growth factors and signaling molecules essential for brain homeostasis. Understanding choroid plexus dysfunction in AD provides insights into disease mechanisms and potential therapeutic targets.
[Alzheimer's disease](/diseases/alzheimers-disease), affecting over 6 million Americans, involves the accumulation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques and [neurofibrillary tangles](/proteins/tau-protein) composed of hyperphosphorylated [tau](/proteins/tau-protein) protein throughout the brain. The choroid plexus, as a major clearance pathway for these proteins, becomes overwhelmed and functionally impaired as the disease progresses. This creates a vicious cycle where impaired clearance accelerates protein accumulation, further compromising choroid plexus function.
The choroid plexus is located in the [lateral ventricles](/brain-regions/lateral-ventricles) (tetrahedral portion), the [third ventricle](/brain-regions/third-ventricle) (roof), and the [fourth ventricle](/brain-regions/fourth-ventricle) (roof and lateral recesses). Each choroid plexus is composed of a core of loose connective tissue containing blood vessels, covered by a single layer of cuboidal epithelial cells that possess distinctive structural and functional characteristics[@redzic2015].
Choroid plexus epithelial cells are joined by tight junctions that constitute the [blood-CSF barrier](/entities/blood-csf-barrier), preventing the free passage of most molecules between the blood and CSF. These cells express numerous transporters, receptors, and enzymes that regulate the composition of CSF and protect the brain from potentially harmful substances in the bloodstream. The selective permeability of the blood-CSF barrier differs from that of the [blood-brain barrier](/entities/blood-brain-barrier), reflecting the distinct physiological roles of these two interfaces[@ghersi-egea2003].
In [Alzheimer's disease](/diseases/alzheimers-disease), the choroid plexus exhibits structural alterations including epithelial cell atrophy, stromal fibrosis, calcification, and [inflammatory changes](/mechanisms/neuroinflammation). Functional impairments include reduced CSF production rate, diminished waste clearance capacity, altered transporter expression, and compromised barrier integrity. These changes contribute to the accumulation of toxic proteins in the brain and the progression of [neurodegenerative processes](/diseases/alzheimers-disease)[@tachida2008].
The blood-CSF barrier represents an important therapeutic target for AD interventions. Unlike the [blood-brain barrier](/entities/blood-brain-barrier), which limits drug penetration into brain tissue, the choroid plexus offers potential access to the CSF compartment. Strategies targeting choroid plexus function may enhance drug delivery to the central nervous system and potentially slow disease progression.
The choroid plexus comprises approximately 70% of the total CSF-producing surface area in humans, with the remainder contributed by the ependymal lining of the ventricular system. The structural organization consists of a core of highly fenestrated capillaries surrounded by a layer of cuboidal epithelial cells, creating a specialized interface that mediates bidirectional transport between blood and CSF[@ching2009].
The epithelial cells of the choroid plexus possess distinctive morphological features including apical microvilli that increase surface area for CSF secretion, basal infoldings that accommodate mitochondrial populations for active transport, and junctional complexes that maintain barrier function. The cytoskeleton of these cells supports their secretory function and contributes to mechanical stability.
The stromal core of the choroid plexus contains connective tissue elements including collagen fibers, fibroblasts, and immune cells. This compartment houses the capillary network that provides the blood supply for CSF production and receives regulatory signals from the epithelial layer. Age-related changes in stromal composition, including increased collagen deposition and reduced cellularity, contribute to functional decline[@stable2016].
CSF production occurs primarily through a combination of filtration and active secretion by choroid plexus epithelial cells. The process involves the movement of plasma from fenestrated capillaries into the epithelial cell cytoplasm, followed by active transport across the apical membrane into the ventricular space. This process requires substantial energy expenditure, as evidenced by the high density of mitochondria in choroid plexus epithelial cells[@carro2007].
The rate of CSF production in adult humans is approximately 500-600 mL per day, representing a complete turnover of the CSF volume approximately 3-4 times daily. This dynamic circulation serves multiple functions including buoyancy protection of the brain, nutrient delivery, waste removal, and hormonal signaling. The choroid plexus maintains strict regulation of CSF composition despite variations in plasma composition.
Ion transporters play a critical role in CSF secretion, with the Na+/K+-ATPase establishing the electrochemical gradient driving fluid movement. The choroid plexus expresses numerous ion channels and transporters including chloride channels, bicarbonate transporters, and aquaporin channels that facilitate water movement. Dysfunction of these transport systems impairs CSF production and composition regulation.
The blood-CSF barrier formed by choroid plexus epithelial cells provides selective access to the CSF compartment while protecting the brain from potentially harmful blood-borne substances. Tight junctions between epithelial cells restrict paracellular transport, while transcellular transport is mediated by specific transporters and receptors[@whone2019].
Transporters expressed by choroid plexus epithelial cells include the multidrug resistance protein (P-glycoprotein), which exports drugs and toxins back to the blood, organic anion transporters (OATs) that mediate the clearance of organic acids, and organic cation transporters (OCTs) that handle amine compounds. This transporter repertoire enables the selective removal of waste products from the CSF while preventing the accumulation of potentially toxic substances.
Receptor-mediated transport across the blood-CSF barrier includes the transferrin receptor, which mediates iron import into the CSF, and the insulin receptor, which facilitates insulin entry into the central nervous system. These pathways provide essential nutrients to the brain while maintaining barrier integrity. The megalin-cubilin receptor complex mediates the endocytic uptake of numerous proteins and represents an important pathway for CSF protein homeostasis.
Glymphatic Anatomy: The glymphatic system consists of:
Epithelial cell degeneration in AD involves cytoplasmic vacuolization, nuclear pyknosis, and reduced mitochondrial density. These changes impair the secretory function of the choroid plexus and contribute to reduced CSF production rates observed in AD patients. The epithelial damage may result from a combination of factors including amyloid toxicity, oxidative stress, and chronic inflammation.
Calcification of the choroid plexus increases with age and is accelerated in AD. These calcium deposits accumulate in the stromal compartment and may physically impair vascular and epithelial function. The relationship between calcification and cognitive decline remains an area of investigation, with some studies suggesting that extensive choroid plexus calcification correlates with disease severity.
Fibrotic changes in the choroid plexus stroma involve increased collagen deposition and reduced fibroblast activity. These changes stiffen the tissue structure and may impair the diffusion of molecules between blood and epithelial cells. The fibrotic response may represent a chronic wound-healing reaction to repeated injury from amyloid toxicity and inflammation.
Reduced CSF production represents a significant functional consequence of choroid plexus dysfunction in AD. Studies measuring CSF production rates using external ventricular drainage techniques have demonstrated reduced output in AD patients compared to healthy controls. This reduction may contribute to altered intracranial dynamics and reduced waste clearance from the brain.
The choroid plexus expresses numerous transporters that mediate the clearance of amyloid-beta and tau from the CSF. In AD, the expression and function of these transporters becomes impaired, reducing the brain's capacity to eliminate toxic proteins. The low-density lipoprotein receptor-related protein 1 (LRP1) and P-glycoprotein are particularly important for amyloid clearance and show reduced expression in AD choroid plexus[@isik2020].
Barrier dysfunction in AD involves both structural and functional changes to the blood-CSF barrier. Leakage of plasma proteins into the CSF, increased white blood cell trafficking, and altered cytokine profiles indicate barrier compromise. This dysfunction may permit the entry of peripheral toxins or immune cells that accelerate neuroinflammation.
The glymphatic system, a perivascular waste clearance pathway discovered in recent years, relies on CSF influx along arterial perivascular spaces, interchange with interstitial fluid, and clearance along venous perivascular routes. The choroid plexus plays an essential role in this system by producing the CSF that drives convective flow through brain parenchyma[@prater2018].
Astrocytic astrocyte end-feet ensheath the cerebral vasculature and regulate glymphatic flow through their water channel aquaporin-4 (AQP4). This perivascular pathway enables the clearance of solutes including amyloid-beta and tau that accumulate in AD. Disruption of glymphatic function contributes to protein accumulation and may represent an early event in disease pathogenesis.
Sleep-related changes in glymphatic activity provide a physiological mechanism for the well-documented relationship between sleep disturbance and AD risk. During sleep, the extracellular space expands, enhancing convective flow and waste clearance. The choroid plexus, by maintaining adequate CSF production, supports this nocturnal clearance function.
Glymphatic dysfunction in AD involves multiple mechanisms including reduced CSF production, altered aquaporin-4 expression, and structural changes in perivascular spaces. Amyloid deposits around cerebral vasculature may physically impede glymphatic flow, creating a positive feedback loop where protein accumulation reduces clearance capacity.
The choroid plexus contributes to glymphatic impairment not only through reduced CSF production but also through altered composition of the secreted fluid. Changes in CSF protein composition, including increased inflammatory mediators and altered ion concentrations, may affect the convective driving force for glymphatic flow.
Perivascular drainage of amyloid along the glymphatic pathway converges on the choroid plexus as a final clearance step. The choroid plexus thus represents a crucial bottleneck where impaired function leads to accumulation of toxic proteins in brain tissue. Strategies to enhance glymphatic function may therefore benefit from targeting choroid plexus activity.
The blood-CSF barrier in AD undergoes structural modifications that increase permeability and permit the entry of potentially harmful substances from blood to CSF and brain. Tight junction proteins including claudin-5, occludin, and ZO-1 show altered expression and distribution in AD choroid plexus, compromising the paracellular seal[@kratzer2020].
Matrix metalloproteinases (MMPs) play important roles in tight junction remodeling under physiological conditions but become dysregulated in AD. Increased MMP activity in the choroid plexus may degrade tight junction proteins and contribute to barrier breakdown. Inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) upregulate MMP expression, creating a positive feedback loop between inflammation and barrier dysfunction.
Oxidative stress in AD affects choroid plexus endothelial and epithelial cells through multiple mechanisms including mitochondrial dysfunction, metal accumulation, and reduced antioxidant capacity. The resulting oxidative damage to cellular components impairs function and may trigger apoptosis. Antioxidant therapies have shown promise in protecting barrier function in preclinical models.
Leakage of plasma proteins into the CSF provides a marker of blood-CSF barrier dysfunction and has been documented in AD patients. The entry of serum albumin into the CSF may contribute to osmotic imbalance and altered brain fluid dynamics. Additionally, the presence of plasma proteins in CSF may promote inflammatory responses.
The entry of blood-borne toxins into the brain through a compromised blood-CSF barrier may contribute to neurodegeneration. Heavy metals, drugs, and environmental toxins that would normally be excluded may gain access to brain tissue. This exposure may be particularly significant in individuals with other risk factors for AD.
Immune cell trafficking across the blood-CSF barrier increases in AD, with elevated numbers of lymphocytes and monocytes detected in CSF. This infiltration may reflect both barrier dysfunction and active recruitment by inflammatory signals. The presence of immune cells in the CSF may contribute to neuroinflammation and disease progression.
The choroid plexus expresses multiple receptors and transporters that mediate amyloid-beta clearance from the CSF. The low-density lipoprotein receptor-related protein 1 (LRP1) on choroid plexus epithelial cells binds Aβ and facilitates its transcytosis into the bloodstream. This pathway represents a crucial elimination route for brain-derived amyloid.
The ATP-binding cassette transporter A1 (ABCA1) promotes cholesterol and amyloid efflux from cells. In AD, ABCA1 expression in the choroid plexus becomes reduced, impairing amyloid clearance capacity. Genetic variants in the ABCA1 gene associate with AD risk, highlighting the importance of this pathway.
Receptor for advanced glycation end products (RAGE) mediates the import of Aβ from blood into brain tissue. The balance between RAGE and LRP1 activity determines the net direction of amyloid transport across the blood-CSF barrier. In AD, RAGE activity predominates, leading to accumulation of amyloid in brain tissue.
Tau protein, normally cleared through multiple pathways including proteolytic degradation, synaptic release, and glymphatic drainage, may also be subject to choroid plexus-mediated clearance. The mechanisms governing tau transport across the blood-CSF barrier remain under investigation but likely involve both receptor-mediated uptake and paracellular leakage.
The choroid plexus expresses receptors that may participate in tau uptake and clearance. The low-density lipoprotein receptor-related protein 2 (LRP2, also known as megalin) can bind tau and mediate its endocytic clearance. Impairment of this pathway in AD may contribute to tau accumulation in brain tissue.
CSF levels of tau and phosphorylated tau serve as diagnostic biomarkers for AD, reflecting neuronal injury and pathology burden. The relationship between CSF tau levels and choroid plexus function may provide insights into disease mechanisms and enable therapeutic monitoring.
Cerebrospinal fluid biomarkers including amyloid-beta 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) provide diagnostic information for AD and reflect underlying pathological changes. Reduced Aβ42 in CSF reflects amyloid deposition in brain tissue, while elevated tau reflects neuronal injury. These biomarkers also correlate with choroid plexus function.
The albumin quotient (CSF albumin/serum albumin) provides a measure of blood-CSF barrier integrity. Elevated albumin quotient in AD indicates barrier dysfunction that may contribute to disease progression. This measure may also inform treatment decisions regarding drug delivery to the central nervous system.
Choroid plexus-derived proteins in CSF may serve as disease biomarkers. S100B protein, produced by choroid plexus epithelial cells, becomes elevated in CSF when these cells are damaged. Measurement of choroid-specific proteins may enable monitoring of choroid plexus health in AD patients.
Protecting choroid plexus function represents a potential therapeutic strategy for AD. Agents that preserve epithelial cell viability, enhance transporter function, and reduce inflammation may slow disease progression by maintaining waste clearance capacity. Several such agents are under investigation in preclinical and clinical studies.
Drug delivery to the brain through the choroid plexus offers an alternative to blood-brain barrier penetration. Intranasal delivery pathways access the CSF via the olfactory epithelium and cribriform plate, reaching the ventricular system and choroid plexus. This approach may enable treatment of choroid plexus pathology while minimizing systemic side effects.
Gene therapy approaches targeting choroid plexus cells may enhance their functional capacity. Viral vector-mediated expression of amyloid-clearing enzymes, transporters, or trophic factors could enhance waste clearance and barrier function. The accessibility of choroid plexus epithelial cells makes them attractive targets for such interventions.
Choroid plexus dysfunction occurs in multiple neurodegenerative conditions beyond AD, including Parkinson's disease, Huntington's disease, and multiple sclerosis. Comparative studies reveal both shared mechanisms and disease-specific patterns of pathology. This overlap suggests that choroid plexus dysfunction may represent a common pathway in neurodegeneration.
In Parkinson's disease, the choroid plexus may contribute to alpha-synuclein clearance. Impaired function may therefore accelerate the accumulation of this protein in brain tissue. The relationship between choroid plexus function and synucleinopathies deserves further investigation.
Multiple system atrophy (MSA), particularly the cerebellar subtype, involves prominent choroid plexus pathology. The choroid plexus in MSA shows distinctive changes including epithelial cell degeneration and reduced secretory function. These findings may inform differential diagnosis and mechanistic understanding.
Magnetic resonance imaging of the choroid plexus has advanced significantly with techniques including contrast-enhanced imaging, diffusion-weighted imaging, and T1 mapping. These approaches enable visualization of choroid plexus volume, perfusion, and microstructure in living subjects. Choroid plexus hypertrophy has been documented in AD and may reflect compensatory responses to functional impairment.
Functional imaging of choroid plexus activity using arterial spin labeling and other perfusion techniques provides information about CSF production rates in vivo. These measures may enable monitoring of choroid plexus function over time and in response to therapeutic interventions.
Positron emission tomography (PET) ligands targeting the choroid plexus may enable visualization of pathological changes. Ligands binding to transporter proteins or inflammatory markers could reveal choroid plexus involvement in disease processes.
Genetic factors influencing choroid plexus function may modulate AD risk. Polymorphisms in transporter genes, tight junction protein genes, and inflammatory mediator genes may affect choroid plexus vulnerability. The identification of such variants may enable risk stratification and personalized therapeutic approaches.
Studies of choroid plexus gene expression in AD have revealed altered patterns of transporter and receptor expression. These changes may inform the development of therapeutic agents targeting choroid plexus function. Induced pluripotent stem cell models of choroid plexus cells from AD patients provide opportunities for mechanistic study.
The choroid plexus, far from being a passive CSF factory, emerges as a crucial player in Alzheimer's disease pathogenesis. Its roles in CSF production, waste clearance, and barrier function make it essential for brain homeostasis, and its dysfunction contributes significantly to the accumulation of toxic proteins and disease progression.
Understanding the mechanisms of choroid plexus dysfunction in AD provides opportunities for therapeutic intervention. Strategies targeting this structure may enhance waste clearance, restore barrier integrity, and potentially slow disease progression. The accessibility of the choroid plexus for drug delivery and biomarker sampling makes it an attractive therapeutic target.
Future research should focus on clarifying the temporal relationship between choroid plexus dysfunction and other AD pathological changes, identifying genetic factors that modulate choroid plexus susceptibility, and developing therapies that preserve or restore choroid plexus function. The integration of choroid plexus-focused approaches into comprehensive AD treatment strategies may significantly improve patient outcomes.
Related Hypotheses: